SCHEMBL1009558

SCHEMBL1009558

CC(NC(=O)CCCn1nc(C(F)(F)F)c2c1CCCC2)c1ccccc1

nearest known ligand 0.75

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.61
HTT P42858 1/20 0.61
POLQ O75417 1/20 0.52
POLB P06746 3/20 0.52
TSHR P16473 2/20 0.50
GAA P10253 1/20 0.50
HSD17B10 Q99714 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
TP53 P04637 2/20 0.49
MEN1 O00255 1/20 0.49
NPC1 O15118 1/20 0.49
KMT2A Q03164 1/20 0.49
MAPT P10636 5/20 0.49
LMNA P02545 2/20 0.49
NPSR1 Q6W5P4 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C19 P33261 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1005581 0.97 ALDH1A1 (0.57) ALDH1A1HTTPOLQPOLBTSHR
SCHEMBL1007605 0.88 POLB (0.63) POLQPOLBTSHRGAAHSD17B10
SCHEMBL1007066 0.86 SMN1; SMN2 (0.63) POLQPOLBTSHRGAAHSD17B10
SCHEMBL1008186 0.85 ALDH1A1 (0.54) ALDH1A1HTTPOLQPOLBTSHR
SCHEMBL1898637 0.85 POLQ (0.52) ALDH1A1HTTPOLQPOLBTSHR
SCHEMBL1007171 0.83 ALDH1A1 (0.67) ALDH1A1HTTPOLQPOLBTSHR
SCHEMBL1006822 0.80 POLB (0.63) ALDH1A1HTTPOLQPOLBTSHR
SCHEMBL1008333 0.80 ALDH1A1 (0.62) ALDH1A1HTTPOLQPOLBTSHR
SCHEMBL1006340 0.79 POLB (0.52) ALDH1A1POLQPOLBTSHRGAA
SCHEMBL1896530 0.79 MAPT (0.69) POLBTSHRTP53MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118236-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 US disclosed
US-20110118236-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 US disclosed
EP-2269990-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-01-05 EP disclosed
EP-2269990-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-01-05 EP disclosed
WO-2009119088-A1 HETEROCYCLIC COMPOUND 武田薬品工業株式会社 (JP) 2009-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118236-A1 HETEROCYCLIC COMPOUND GRIN1, GRM1, GRIK1 ALDH1A1 614/4885HTT 3487/4885POLQ 3429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.